• Legal Era India
  • Legal Era Global
  • Membership
  • Sign inSUBSCRIBE
Legal Era
X
Sign in
  • Home
  • News
    +
    • From the Courts
    • Policy & Law
    • Supreme Court (India)
    • High Court (India)
    • TAX Updates
    • MARKET WATCH
    • Deal Street
    • Global Insights
    • IBC Cases
    • Hires & Moves
    • IP News
    • Competition Verdict
    • Global Articles
    • Global Deals
  • Articles
    +
    • ABOUT THE LAW
    • AWARDS & ACCOLADES
    • Aerospace
    • Agriculture
    • Alternate Dispute Resolution
    • Banking and Finance
    • Bankruptcy
    • Book Review
    • Bribery & Corruption
    • Commercial Litigation
    • Competition Law
    • Conference Reports
    • Consumer Products
    • Contract
    • Corporate Governance
    • Corporate Law
    • Covid-19
    • Cryptocurrency
    • Cybersecurity
    • Data Protection
    • Defence
    • Digital Economy
    • E-commerce
    • Employment Law
    • Energy and Natural Resources
    • Entertainment and Sports Law
    • Environmental Law
    • FDI
    • Food and Beverage
    • Health Care
    • IBC Diaries
    • Insurance Law
    • Intellectual Property
    • International Law
    • Labour Laws
    • Litigation
    • Litigation Funding
    • Manufacturing
    • Mergers & Acquisitions
    • NFTs
    • Privacy
    • Private Equity
    • Project Finance
    • Real Estate
    • Risk and Compliance
    • Technology Media and Telecom
    • Tributes
    • Zoom In
    • Take On Board
    • In Focus
    • Law & Policy and Regulation
    • IP & Tech Era
    • Viewpoint
    • Arbitration & Mediation
    • Tax
    • Student Corner
    • ESG
    • Gaming
    • Inclusion & Diversity
  • Law Firms
    +
    • Global Law Firm
    • Asia Law Firm
    • India Law Firm
  • In-House
  • Rankings
  • E-Magazine
  • Legal Era TV
  • Legal Era TV
  • Events
  • News
    • From the Courts
    • Policy & Law
    • Supreme Court (India)
    • High Court (India)
    • TAX Updates
    • MARKET WATCH
    • Deal Street
    • Global Insights
    • IBC Cases
    • Hires & Moves
    • IP News
    • Competition Verdict
    • Global Articles
    • Global Deals
  • Articles
    • ABOUT THE LAW
    • AWARDS & ACCOLADES
    • Aerospace
    • Agriculture
    • Alternate Dispute Resolution
    • Banking and Finance
    • Bankruptcy
    • Book Review
    • Bribery & Corruption
    • Commercial Litigation
    • Competition Law
    • Conference Reports
    • Consumer Products
    • Contract
    • Corporate Governance
    • Corporate Law
    • Covid-19
    • Cryptocurrency
    • Cybersecurity
    • Data Protection
    • Defence
    • Digital Economy
    • E-commerce
    • Employment Law
    • Energy and Natural Resources
    • Entertainment and Sports Law
    • Environmental Law
    • FDI
    • Food and Beverage
    • Health Care
    • IBC Diaries
    • Insurance Law
    • Intellectual Property
    • International Law
    • Labour Laws
    • Litigation
    • Litigation Funding
    • Manufacturing
    • Mergers & Acquisitions
    • NFTs
    • Privacy
    • Private Equity
    • Project Finance
    • Real Estate
    • Risk and Compliance
    • Technology Media and Telecom
    • Tributes
    • Zoom In
    • Take On Board
    • In Focus
    • Law & Policy and Regulation
    • IP & Tech Era
    • Viewpoint
    • Arbitration & Mediation
    • Tax
    • Student Corner
    • ESG
    • Gaming
    • Inclusion & Diversity
  • Law Firms
    • Global Law Firm
    • Asia Law Firm
    • India Law Firm
  • In-House
  • Rankings
  • E-Magazine
  • Legal Era TV
  • Legal Era TV
  • Events
search-icon

Top Stories

MSN Lab starts Phase 3 trials for Molnupiravir drug treating mild Covid-19 patients
HomeNewsIP News
IP News

MSN Lab starts Phase 3 trials for Molnupiravir drug treating mild Covid-19 patients

By Legal Era
26 May 2021 7:30 AM GMT

MSN Lab starts Phase 3 trials for Molnupiravir drug treating mild Covid-19 patients

MSN Lab starts Phase 3 trials for Molnupiravir drug treating mild Covid-19 patients

MSN Lab starts Phase 3 trials for Molnupiravir drug treating mild Covid-19 patients Getting clearance from the Drug Controller of India for conducting the clinical trial, MSN Laboratories announced that they start with the Phase 3 clinical trial of the molnupiravir capsule. This drug will be used to treat mild-to-moderate covid-19 patients. The company will soon start the clinical trial...

ToRead the Full Story, Subscribe to Legal Era

Access the exclusive LEGAL ERAStories,Editorial and Expert Opinion

Subscribe Now
AlreadyaSubscriber?SigninNow
View Plans

MSN Lab starts Phase 3 trials for Molnupiravir drug treating mild Covid-19 patients

Getting clearance from the Drug Controller of India for conducting the clinical trial, MSN Laboratories announced that they start with the Phase 3 clinical trial of the molnupiravir capsule. This drug will be used to treat mild-to-moderate covid-19 patients.

The company will soon start the clinical trial at more than 40 sites across India. The trial will be done on more than 2400 patients suffering from mild to moderate covid-19. After Natco Pharma and Hetero Labs, MSN will be the third firm to start the trial for the drug. Both Natco and Hetero trials are underway.

The drug Molnupiravir, which was initially developed by US-based Ridgeback Biotherapeutics, is an experimental drug whose study is undergoing the Covid-19 treatment globally. Ridgeback partnered with Merck & Co. for further development. Merck has signed voluntary licensing agreements with Cipla Ltd, Dr. Reddy's Laboratories, Emcure Pharmaceuticals Ltd, Hetero Labs Ltd, and Sun Pharmaceutical Industries Ltd, allowing the drug to be manufactured and marketed in India.

Merck Sharp & Dohme is also conducting the same phase 3 trials for the treatment of confirmed Covid-19 patients but is not hospitalized. MSN is not a part of the voluntary licensing agreement and is also not related to Merck Sharp and Natco. But they are nevertheless going ahead with their trials.

The company said its research and development team has developed both the active pharmaceutical ingredient and formulation for the drug and is expecting to launch soon after the successful conclusion of the clinical study followed by regulatory approval.

Next Story
TAGS:
  • #Covid-19
  • #Mild-to-moderate
  • #MSN
  • #Natco
  • #Molnupiravir
  • #Hetero Labs
  • #Phase 3 Clinical trials
Similar Posts
Trending Now
Recommended Articles
  • News
  • From the Courts
  • Supreme Court (India)
  • High Court (India)
  • Global Insights
  • Deal Street
  • Hires & Moves
  • Refund & Cancellation Policy
  • Articles
  • Zoom In
  • Take On Board
  • In Focus
  • Law & Policy
  • IP & Tech Era
  • Viewpoint
  • Arbitration & Mediation
  • Tax
  • Student Corner
  • Interviews
  • Law Firms
  • E-Magazine
  • Legal Era TV
  • Membership
  • Reader's Feedback
  • Cartoons
  • Subscribe
  • Advertise
Follow Us
Subscribe Newsletter
  • 2023© All rights reserved Legal Era Media Group
  • Who We Are
  • Careers
  • Advertise with Us
  • Contact Us
  • Privacy Policy
  • Terms and Conditions
Powered by  Hocalwire
X
X